Vascular endothelial growth factor receptor-2: Structure, function, intracellular signalling and therapeutic inhibition

被引：837

作者：

Holmes, Katherine ^{[1
]}

Roberts, Owain Ll ^{[1
]}

Thomas, Angharad M. ^{[1
]}

Cross, Michael J. ^{[1
]}

机构：

[1] Univ Wales, NWCRF Inst, Sch Biol Sci, Coll Nat Sci, Bangor LL57 2UW, Gwynedd, Wales

来源：

CELLULAR SIGNALLING | 2007年 / 19卷 / 10期

基金：

英国医学研究理事会;

关键词：

VEGF; VEGFR-2; angiogenesis; endothelial; inhibitors; signal transduction; PROTEIN-KINASE-C; FOCAL ADHESION KINASE; NITRIC-OXIDE SYNTHASE; KDR VEGF RECEPTOR-2; TYROSINE KINASE; ADAPTER PROTEIN; TUMOR ANGIOGENESIS; FACTOR GENE; PERMEABILITY FACTOR; DOMAIN RECEPTOR;

D O I：

10.1016/j.cellsig.2007.05.013

中图分类号：

Q2 [细胞生物学];

学科分类号：

071009 ; 090102 ;

摘要：

Vascular endothelial growth factors (VEGFs) regulate vascular development, angiogenesis and lymphangiogenesis by binding to a number of receptors. VEGFR-I is required for the recruitment of haematopoietic stein cells and the migration of monocytes and macrophages, VEGFR-2 regulates vascular endothelial function and VEGFR-3 regulates lymphatic endothelial cell function. Over the last decade, considerable progress has been made in delineating the VEGFR-2 specific intracellular signalling cascades leading to proliferation, migration, survival and increased permeability, each of which contributes to the angiogenic response. Furthermore, therapeutic inhibition of VEGFR-2 action is now having an impact in the clinic for the treatment of a number of diseases. (c) 2007 Elsevier Inc. All rights reserved.

引用

页码：2003 / 2012

页数：10

共 113 条

[1] cDNA microarray analysis of the gene expression profile of VEGF-activated human umbilical vein endothelial cells [J].

Abe M. ;

Sato Y. .

Angiogenesis, 2001, 4 (4) :289-298

[2] A review of the latest clinical compounds to inhibit VEGF in pathological angiogenesis [J].

Baka, Sofia ;

Clamp, Andrew R. ;

Jayson, Gordon C. .

EXPERT OPINION ON THERAPEUTIC TARGETS, 2006, 10 (06) :867-876

[3] Regulation of microvascular permeability by vascular endothelial growth factors [J].

Bates, DO ;

Hillman, NJ ;

Williams, B ;

Neal, CR ;

Pocock, TM .

JOURNAL OF ANATOMY, 2002, 200 (06) :581-597

[4]

Bates DO, 2002, CANCER RES, V62, P4123

[5] Neuropilin-1 regulates vascular endothelial growth factor-mediated endothelial permeability [J].

Becker, PM ;

Waltenberger, J ;

Yachechko, R ;

Mirzapoiazova, T ;

Sham, JSK ;

Lee, CG ;

Elias, JA ;

Verin, AD .

CIRCULATION RESEARCH, 2005, 96 (12) :1257-1265

[6] Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis [J].

Bergers, G ;

Brekken, R ;

McMahon, G ;

Vu, TH ;

Itoh, T ;

Tamaki, K ;

Tanzawa, K ;

Thorpe, P ;

Itohara, S ;

Werb, Z ;

Hanahan, D .

NATURE CELL BIOLOGY, 2000, 2 (10) :737-744

[7] VASCULAR-PERMEABILITY FACTOR (VASCULAR ENDOTHELIAL GROWTH-FACTOR) GENE IS EXPRESSED DIFFERENTIALLY IN NORMAL-TISSUES, MACROPHAGES, AND TUMORS [J].

BERSE, B ;

BROWN, LF ;

VANDEWATER, L ;

DVORAK, HF ;

SENGER, DR .

MOLECULAR BIOLOGY OF THE CELL, 1992, 3 (02) :211-220

[8] Vascular endothelial growth factor in amyotrophic lateral sclerosis and other neurodegenerative diseases [J].

Bogaert, Elike ;

Van Damme, Philip ;

Van Den Bosch, Ludo ;

Robberecht, Wim .

MUSCLE & NERVE, 2006, 34 (04) :391-405

[9] INTEGRIN ALPHA(V)BETA(3) ANTAGONISTS PROMOTE TUMOR-REGRESSION BY INDUCING APOPTOSIS OF ANGIOGENIC BLOOD-VESSELS [J].

BROOKS, PC ;

MONTGOMERY, AMP ;

ROSENFELD, M ;

REISFELD, RA ;

HU, TH ;

KLIER, G ;

CHERESH, DA .

CELL, 1994, 79 (07) :1157-1164

[10] Akt promotes cell survival by phosphorylating and inhibiting a forkhead transcription factor [J].

Brunet, A ;

Bonni, A ;

Zigmond, MJ ;

Lin, MZ ;

Juo, P ;

Hu, LS ;

Anderson, MJ ;

Arden, KC ;

Blenis, J ;

Greenberg, ME .

CELL, 1999, 96 (06) :857-868

← 1 2 3 4 5 6 7 8 9 10 →